2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Esperance Pharmaceuticals Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer EP-100, Paclitaxel - Ovarian Cancer Recurrent | Phase 2 | Completed | Esperance Pharmaceuticals Inc | 49 | 2012-02-01 | 2014-06-10 |
| Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors EP-100 - Solid Tumors, Advanced Solid Tumors | Phase 1 | Completed | Esperance Pharmaceuticals Inc | 38 | 2009-07-01 | 2012-04-04 |
EP-100 membrane-disrupting peptide (2) · Paclitaxel (1)
United States (2)